Dupilumab Shown to Reduce COPD Exacerbations Substantially in New Phase 3 Data

This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.

Related Keywords

,Georged Yancopoulos ,Naimish Patel ,Regeneron Pharmaceuticals Inc ,Drug Administration ,Regeneron Pharmaceuticals ,Breakthrough Therapy ,Significantly Reduced ,Second Positive Phase ,Confirming Potential ,Become First Approved Biologic ,Copd ,Pulmonology ,Dupilumab ,Phase 3 ,Dupixent ,Exacerbations ,